floxacillin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, 6-aminopenicillanic acid derivatives	1183	5250-39-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: floxacillin fluocloxacilin flucloxacillin fluoxacillin flucloxacillin sodium	Antibiotic analog of CLOXACILLIN. Molecular weight: 453.87 Formula: C19H17ClFN3O5S CLOGP: 2.70 LIPINSKI: 0 HAC: 8 HDO: 2 TPSA: 112.74 ALOGS: -3.92 ROTB: 3

Molecule

Description

Molfile Inchi Smiles

Synonyms:

floxacillin
fluocloxacilin
flucloxacillin
fluoxacillin
flucloxacillin sodium

Antibiotic analog of CLOXACILLIN.

Molecular weight: 453.87
Formula: C19H17ClFN3O5S
CLOGP: 2.70
LIPINSKI: 0
HAC: 8
HDO: 2
TPSA: 112.74
ALOGS: -3.92
ROTB: 3

Drug dosage:

Dose	Unit	Route
2	g	O
2	g	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	60 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Hosey CM, Chan R, Benet LZ
CL (Clearance)	2.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
MRTD (Maximum Recommended Therapeutic Daily Dose)	146.96 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
t_half (Half-life)	1.40 hours	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.19 L/kg	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.05 mg/mL	Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma)	0.04 %	Lombardo F, Berellini G, Obach RS

Showing 1 to 8 of 8 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1962	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Metabolic acidosis	336.18	25.69	136	6074	44933	63437879
Drug interaction	149.37	25.69	145	6065	228986	63253826
Cellulitis	114.80	25.69	81	6129	81877	63400935
Pyroglutamic acidosis	113.13	25.69	23	6187	612	63482200
Pyroglutamate increased	90.68	25.69	18	6192	423	63482389
Swelling face	56.52	25.69	48	6162	63427	63419385
Neutropenic sepsis	53.67	25.69	28	6182	16410	63466402
Jaundice	50.63	25.69	33	6177	29218	63453594
Hiccups	48.69	25.69	15	6195	2216	63480596
Dermatitis allergic	44.36	25.69	24	6186	15124	63467688

Showing 1 to 10 of 29 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug interaction	153.02	21.58	167	4433	225779	34726552
Metabolic acidosis	147.71	21.58	84	4516	43596	34908735
Pyroglutamic acidosis	127.63	21.58	25	4575	401	34951930
Pyroglutamate increased	80.41	21.58	16	4584	279	34952052
Drug reaction with eosinophilia and systemic symptoms	69.47	21.58	47	4553	32965	34919366
Drug level decreased	62.23	21.58	27	4573	7819	34944512
Immunosuppressant drug level decreased	61.99	21.58	17	4583	1237	34951094
Stevens-Johnson syndrome	57.95	21.58	34	4566	18605	34933726
Kounis syndrome	38.76	21.58	14	4586	2504	34949827
Acute kidney injury	38.55	21.58	107	4493	304881	34647450

Showing 1 to 10 of 24 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Metabolic acidosis	425.86	19.67	212	10538	82317	79651321
Drug interaction	283.14	19.67	312	10438	414871	79318767
Pyroglutamic acidosis	224.95	19.67	47	10703	1029	79732609
Pyroglutamate increased	166.35	19.67	34	10716	665	79732973
Cellulitis	104.84	19.67	99	10651	108961	79624677
Drug level decreased	104.81	19.67	47	10703	14355	79719283
Drug reaction with eosinophilia and systemic symptoms	61.07	19.67	58	10692	64186	79669452
Immunosuppressant drug level decreased	57.87	19.67	18	10732	1986	79731652
Acute kidney injury	56.77	19.67	176	10574	519228	79214410
Lip swelling	55.05	19.67	45	10705	40866	79692772

Showing 1 to 10 of 56 entries

Previous1 2 3 4 5 6Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	J01CF05	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE BETA-LACTAM ANTIBACTERIALS, PENICILLINS Beta-lactamase resistant penicillins
CHEBI has role	CHEBI:36047	antibacterial drugs
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Showing 1 to 4 of 4 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.76	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
Androgen receptor	Nuclear hormone receptor	P10275	ANDR_HUMAN	IC50	6.25	WOMBAT-PK
Matrix metalloproteinase-9	Enzyme	P14780	MMP9_HUMAN	IC50	4.19	WOMBAT-PK
Penicillin-binding protein 1A	Enzyme		PBPA_CLOPE			WOMBAT-PK

Showing 1 to 3 of 3 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
003516	NDDF
003517	NDDF
10910	IUPHAR_LIGAND_ID
21319	PUBCHEM_CID
2308	INN_ID
235750	RXNORM
387544009	SNOMEDCT_US
426208000	SNOMEDCT_US
43B2M34G2V	UNII
96067005	SNOMEDCT_US

Showing 1 to 10 of 17 entries

Previous1 2Next

Pharmaceutical products:

None